Rituximab in the treatment of thyroid eye disease: Science fiction?

Orbit

Volumn 28, Issue 4, 2009, Pages 251-255

  Salvi, Mario ^a   Vannucchi, Guia ^a   Campi, Irene ^a   Beck Peccoz, Paolo ^a  

^a Dipartimento di Scienze Mediche   (Italy)

Author keywords

Corticosteroids; Graves orbitopathy; Immunosuppression; Rituximab

Indexed keywords

GLUCOCORTICOID; INTERLEUKIN 1 ANTIBODY; RITUXIMAB; THIAMAZOLE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; B LYMPHOCYTE; DRUG TOLERABILITY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THYROID FUNCTION TESTS; TREATMENT OUTCOME;

EID: 70350694454     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.3109/01676830903104611     Document Type: Article

References (29)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves'ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168-199.
2. Bahn RS. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003;88:1939-1946.
3. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78. (Pubitemid 28042269)
4. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxiDe H synthase-2 expression: insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998;273:19615-19625.
5. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab. 2007;92:59-64.
6. Davidson A, Diamond B. Autoimmune diseases. New Engl J Med. 2001;345:340-350.
7. Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenessis. J Immunol. 2007;178:3281-3287.
8. Drexhage HA. Are there more than antibodies to the thryoidstimulating hormone receptor that meet the eye in Graves' disease? Endocrinology. 2006;147:9-12.
9. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Essen J, Morgenthaler NG. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf). 2004;61:612-618.
10. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte Depletion. Thyroid. 2006;16:709-710 (Letter).
11. Garrity JA, Bahn RS. Pathogenesis of Graves' ophthalmopathy: implications for prediction, prevention and treatment. Am J Ophthalmol. 2006;142:147-153.
12. Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1 beta in orbital fibroblasts: implications for the pathogenesis of thyroidassociated ophthalmopathy. Endocrinology. 2006;147: 13-19.
13. Kubota S, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Kuma K, Miyauchi A. Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti- TSH receptor antibodies and clinical outcome in Graves' disease. Endocr J. 2005;52: 735-741.
14. Male D, Cooke A, Owen M, Trowsdale J, Champion B. Antigen receptor molecules. In: AdVanced Immunology. London: Mosby, 1996;2.1-2.2.
15. Nakahara H, Nishimoto N. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006; 6:373-381.
16. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action Amer J Transplant. 2006;6:859-866.
17. Pritchard J, Horst N, Cruikshank W, Smith TJ. Immunoglobulin acxtivation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor 1 receptor pathway. J Immunol. 2003;170:6348-6354.
18. Ratiglia R. Beck-Peccoz P. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell Depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006;154: 511-517.
19. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-New mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.
20. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol. 2005; 238:67-75.
21. RuDerman E, Pope R. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator fro the treatment of rheumatoid arthritis. Arthritis Res Ther. 2005; 7(Suppl 2):S21-S25.
22. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol. 2000;143:197-202.
23. Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck- Peccoz P. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD 20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33-40.
24. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheumat. 2004; 50:3580-3590.
25. Sidner RA, Book BK, Agarwal A, BearDen CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo Depletion with rituximab, anti-human CD 20 monoclonal antibody. Human Antibodies. 2004;13:55-62.
26. Tsokos GC. B Cells, Be Gone- B-Cell Depletion in the treatment of rheumatoid arthritis. N Engl J Med. 2004; 350: 2546-2548.
27. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferatoractivated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002; 87:2352-2358.
28. Wakelkamp IM, Bakker O, BalDeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf). 2003;58:280-287.
29. Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw. 2000;11:153-160.